Paragon 28
-
Extremities
Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System
Paragon 28’s first in the world 3D-printed Patient Specific Talus Spacer. Use in treatment of avascular necrosis (AVN). FDA approval:…
Read More » -
Financial
Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
ENGLEWOOD, Colo., August 2, 2023–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively…
Read More » -
Extremities
Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System
Gorilla® SMO Anterior Dome, Medial Closing Wedge, and Medial Opening Wedge Plating Configurations ENGLEWOOD, Colo., May 23, 2023–(BUSINESS WIRE)–Paragon 28,…
Read More » -
Financial
Paragon 28 Reports First Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
ENGLEWOOD, Colo., May 5, 2023–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively…
Read More » -
Extremities
Paragon 28 Launches Phantom® Metatarsal Shortening System
ENGLEWOOD, Colo., April 24, 2023–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of its Phantom® Metatarsal…
Read More » -
Financial
Paragon 28 Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
March 2, 2023 ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the…
Read More » -
Financial
Paragon 28, Inc. Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
February 17, 2023 ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the…
Read More » -
Financial
Paragon 28, Inc. Announces Proposed Public Offering of Common Stock
January 25, 2023 ENGLEWOOD, Colo.–(BUSINESS WIRE)– Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on…
Read More » -
Financial
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
January 10, 2023 ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively…
Read More » -
Financial
Paragon 28 Reports Third Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
November 10, 2022 ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the…
Read More » -
Extremities
Paragon 28 Launches Mobile Medical Education Lab Tour, Expanding Opportunities for Foot and Ankle Surgeon Education
July 13, 2022 ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot…
Read More » -
Extremities
Paragon 28 Launches Monkey Rings™ Circular External Fixation System
June 9, 2022 ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot…
Read More » -
Extremities
Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair
May 19, 2022 ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot…
Read More » -
Extremities
Paragon 28 Expands Soft Tissue Portfolio with Grappler™ Suture Anchor System Launch
May 17, 2022 ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot…
Read More » -
Financial
Paragon 28 Reports First Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
May 9, 2022 ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the…
Read More »